News: $2.7 Million Grant Awarded to Fund Research on ...


News: $2.7 Million Grant Awarded to Fund Research on the Use of CXCL10 in Avoiding Kidney Graft Rejection

CHIMb.ca
[img]

News: $2.7 Million Grant Awarded to Fund Research on the Use of CXCL10 in Avoiding Kidney Graft Rejection

Team: Events, Training & News

Date: This is not a timed event.

Description


November 2016 - As a part of CIHR’s Project Scheme Grant, CHI’s Dr. Atul Sharma and University of Manitoba’s Dr. Julie Ho received a $2.7 million grant for their research study on detecting rejection rates in patients receiving kidney transplants using Quantitative Urine Metabolomics and CXCL10.

Over 41,931 Canadians suffer from end-stage kidney failure. This number has been increasing steadily for some time now, with failure rates going up by 35 per cent since 2004. Transplantation is the therapy of choice for many patients due to improved survival & quality of life.

A major challenge to transplants, however, is to optimize anti-rejection therapies to balance the risk of organ rejection in patients. Ideally, to avoid complications, patients would need to undergo minimal therapy while preventing rejection. In the first year post-transplant, 30 per cent of patients have rejection of which two-thirds is not detected by clinical markers. Accurate non-invasive tests are required so rejection can be treated early and anti-rejection therapy optimized.

CHI’s Data Science platform is collaborating with multiple centers across Canada with patients from Winnipeg, Ottawa, Toronto, London, Quebec City and Basel, Switzerland. The team has identified new urine diagnostic (detect rejection) and prognostic (predict outcome) tests in kidney transplantation. Based on preliminary findings, the team assessed that urine CXCL10 might produce greater results in detecting rejection when compared to standard-of-care tests. The primary goal of this multi-center, randomized clinical trial is to evaluate the effectiveness of urine CXCL10 to detect early pre-clinical and clinical rejection and determine if treatment improves important kidney transplant outcomes.

CHI Platforms Involved: Clinical Trials, Data Science, Knowledge Translation, Project Management